Press Releases

Current Articles | Categories | Search | Syndication

21 October 2014  Joanne Hunter
New alpha+ Pipettes Great Performance at a Great Price
By Joanne Hunter @ 09:17 :: 18 Views


For unsurpassed pipetting accuracy at a very affordable price you can’t beat the new alpha+ pipettes from Alpha Laboratories (Eastleigh, UK). With an attractive modern design these lightweight, easy-to-use pipettes are robust and reliable even in the most challenging environments. The range includes variable and fixed volume single channel, plus 8- and 12-channel models. 

Read More

17 October 2014  Rebecca Bellars
Abbott's RealTime High Risk HPV Test is Now Available in Europe for Primary Screening for Cervical Cancer
By Rebecca Bellars @ 15:11 :: 73 Views



Abbott's DNA test for the detection of high-risk human papillomavirus (HR HPV) is now available in Europe as an important tool for first-line screening. The test is able to identify women at increased risk for development of cervical cancer or the presence of high-grade disease.

Read More

16 October 2014  Joanne Hunter
Appointment of Non-Executive Director
By Joanne Hunter @ 12:10 :: 77 Views


16 October, 2014 – The Board of Proteome Sciences is pleased to announce the appointment of Mr. Martin Diggle as a Non-Executive Director with immediate effect.

Read More

09 October 2014  Joanne Hunter
Roche Acquires Rights to Technology and Patent Applications from AbVitro to Support Next-Generation Sequencing Pipeline
By Joanne Hunter @ 14:03 :: 116 Views

Pleasanton, CA, USA,  October 9, 2014 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it made a technology acquisition from AbVitro Inc, a company focused on therapeutic target discovery. Roche obtained exclusive rights to a primer extension based target enrichment technology and associated patent applications filed by AbVitro.  Under the terms of the agreement, AbVitro and Roche scientists will collaborate on the development and application of the technology.

Read More

09 October 2014  Joanne Hunter
Randox TxB Cardio Assay gains CE Approval
By Joanne Hunter @ 11:17 :: 109 Views

Global diagnostics company Randox Laboratories has secured CE marking for their TxB Cardio Assay. TxB Cardio is used to measure the effectiveness of aspirin (ASA), a drug which is used therapeutically around the world for its blood thinning properties. Clinical studies have shown that up to 25-30% of all patients who regularly take low doses of the drug are resistant to its full affects, meaning that these patients are at a considerably increased risk of a future cardiovascular event.

Read More

30 September 2014  Joanne Hunter
UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30th JUNE 2014
By Joanne Hunter @ 10:28 :: 123 Views

HIGHLIGHTS 

  • Commercial

o   Strong underlying growth in biomarker services

o   TMT® reagents sales increased 98%

o   Blood test predicting progression from MCI to Alzheimer’s Disease (AD)

o   Biological results underline performance of CK1d compounds reducing tau damage

o   SysQuant® coverage increased 4-fold to over 23,000 phosphorylation sites

o   SysQuant® delivered outstanding results in pancreatic cancer and in Alzheimer’s – CK1d compounds

Read More

30 September 2014  Joanne Hunter
Abcodia Receives Horizon 2020 Grant to Advance its Pancreatic Cancer Early Diagnosis Test
By Joanne Hunter @ 09:50 :: 133 Views


  • Abcodia wins European Commission grant to advance early diagnosis of pancreatic cancer  
  • Development of an innovative new early diagnostic for pancreatic cancer in healthy individuals at high risk of developing the disease
  • Technology developed in collaboration with renowned biostatistician Prof Carlo Berzuini from The University of Manchester
Read More

25 September 2014  Joanne Hunter
New Arrow™ cell separation and molecular extraction product developments revealed at Diasorin Molecular Distributor Meeting
By Joanne Hunter @ 11:47 :: 145 Views

The recently launched CellSep Advanced kit, for use in combination with the Arrow™ Instrument for the automated isolation of up to three cell types directly from whole blood or buffy coat1, was among the new developments revealed to distributors at the Annual DiaSorin Molecular Distributor Meeting held in Bandol, South of France.  As demand for more automated methods for molecular diagnostics and research increases, DiaSorin aims to ensure that its distributors are equipped to meet the evolving needs of customers.

Read More

25 September 2014  Joanne Hunter
Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer’s disease and monitor treatment efficacy
By Joanne Hunter @ 10:55 :: 138 Views

London, September 25th 2014. Proteome Sciences plc (‘Proteome Sciences’) is pleased to announce that its PS Biomarker Services Division has been selected to develop diagnostic products for Genting TauRx Diagnostic Centre Sdn. Bhd. (‘GTD’), an affiliate of TauRx Therapeutics Ltd (‘TauRx Therapeutics’).  The project will involve PS analysing blood samples from patients enrolled in a phase 3 trial of the experimental Alzheimer’s drug LMTX, targeting the tau pathway, and from age-matched controls.  LMTX is being developed by TauRx Therapeutics for the treatment for Alzheimer’s disease of mild to moderate severity.

Read More

25 September 2014  Joanne Hunter
Merck KGaA to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry
By Joanne Hunter @ 08:46 :: 143 Views

  • Merck KGaA to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)
  • • Acquisition expands EMD Millipore’s global reach, increasing the company’s 
  • presence in North America and adding exposure to fast-growing Asian markets 
  • • Customers benefit from broader offering of complementary products and 
  • capabilities and leading e-commerce platform in the industry
  • • Merck KGaA plans to maintain significant presence in St. Louis, MO, 
  • and Billerica, MA
  • • Life Science contribution to Merck KGaA earnings more than doubles
  • • Transaction expected to be immediately accretive to EPS pre and EBITDA margin
  • • Merck KGaA to host media conference call today at 8:00 AM EDT / 2:00 PM CET
Read More

Previous Page | Next Page